Venrock Adviser, LLC — 13F Holdings & Portfolio

CIK 1615982 · latest 13F-HR filed 2026-05-15

Venrock Adviser, LLC manages $2.68B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are APGE (26.68%), ERAS (9.89%), ORKA (7.60%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 8 new positions, exited 2, added to 15, and trimmed 9.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$2.68B

Long-equity book

Holdings

33

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+8 / −2 / ↑15 / ↓9

vs 2025-12-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • ERASCA INC$198.6M +299.0%
  • ORUKA THERAPEUTICS INC$77.7M +61.8%
  • APOGEE THERAPEUTICS INC$73.8M +11.5%
  • SPYRE THERAPEUTICS INC$65.2M +54.0%
  • DIANTHUS THERAPEUTICS INC$57.8M +140.3%
Show all 15

Top Trims

  • VIRIDIAN THERAPEUTICS INC-$44.9M -37.1%
  • CYTOMX THERAPEUTICS INC-$19.4M -29.2%
  • MAZE THERAPEUTICS INC-$16.3M -25.5%
  • CYBIN INC-$12.9M -41.1%
  • ENGENE HOLDINGS INC-$10.6M -24.6%
Show all 9

New Positions

  • DAMORA THERAPEUTICS INC$93.3M
  • RELMADA THERAPEUTICS INC$33.7M
  • TENAX THERAPEUTICS INC$26.8M
  • ADLAI NORTYE LTD$22.2M
  • CENTURY THERAPEUTICS INC$19.7M
Show all 8

Exited Positions

  • UPSTREAM BIO INC$31.7M
  • CASI PHARMACEUTICALS INC$839.2K
Show all 2
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 APOGEE THERAPEUTICS INC APGE 03770N101 $714.9M 26.68% 8,493,321 SH
2 ERASCA INC ERAS 29479A108 $265.1M 9.89% 16,382,812 SH
3 ORUKA THERAPEUTICS INC ORKA 687604108 $203.5M 7.60% 4,148,428 SH
4 SPYRE THERAPEUTICS INC SYRE 00773J202 $185.9M 6.94% 3,685,448 SH
5 KALVISTA PHARMACEUTICALS INC KALV 483497103 $130.3M 4.86% 6,474,485 SH
6 DIANTHUS THERAPEUTICS INC DNTH 252828108 $99.0M 3.70% 1,180,000 SH
7 DAMORA THERAPEUTICS INC DMRA 36322Q206 $93.3M 3.48% 3,603,595 SH
8 OCULAR THERAPEUTIX INC OCUL 67576A100 $87.6M 3.27% 10,346,926 SH
9 COGENT BIOSCIENCES INC COGT 19240Q201 $77.0M 2.87% 2,000,000 SH
10 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $75.9M 2.83% 3,882,709 SH
11 SAVARA INC SVRA 805111101 $75.0M 2.80% 13,740,375 SH
12 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $67.7M 2.53% 1,726,331 SH
13 ORIC PHARMACEUTICALS INC ORIC 68622P109 $54.7M 2.04% 4,319,765 SH
14 VOR BIOPHARMA INC VOR 929033207 $54.3M 2.03% 3,041,719 SH
15 MAZE THERAPEUTICS INC MAZE 578784100 $47.8M 1.78% 1,602,034 SH
16 CYTOMX THERAPEUTICS INC CTMX 23284F105 $46.9M 1.75% 9,982,124 SH
17 JADE BIOSCIENCES INC JBIO 008064206 $45.2M 1.69% 3,220,364 SH
18 DYNE THERAPEUTICS INC DYN 26818M108 $39.4M 1.47% 2,173,913 SH
19 CRESCENT BIOPHARMA INC. CBIO G2545C104 $39.2M 1.46% 2,133,576 SH
20 ZURA BIO LTD ZURA G9TY5A101 $38.3M 1.43% 6,434,990 SH
21 RELMADA THERAPEUTICS INC RLMD 75955J402 $33.7M 1.26% 4,843,380 SH
22 ENGENE HOLDINGS INC ENGNW 29286M105 $32.5M 1.21% 4,771,414 SH
23 TENAX THERAPEUTICS INC TENX 88032L605 $26.8M 1.00% 1,675,262 SH
24 ADLAI NORTYE LTD ANL 00704R109 $22.2M 0.83% 3,212,731 SH
25 CENTURY THERAPEUTICS INC IPSC 15673T100 $19.7M 0.73% 8,695,652 SH
26 CULLINAN THERAPEUTICS INC CGEM 230031106 $19.6M 0.73% 1,379,965 SH
27 CYBIN INC HELP 23256X407 $18.5M 0.69% 3,851,654 SH
28 SURROZEN INC SRZN 86889P208 $18.4M 0.69% 632,931 SH
29 SEPTERNA INC SEPN 81734D104 $12.2M 0.45% 506,056 SH
30 KORRO BIO INC KRRO 500946108 $11.4M 0.43% 1,009,500 SH
31 ALTO NEUROSCIENCE INC ANRO 02157Q109 $11.2M 0.42% 500,000 SH
32 ARTIVA BIOTHERAPEUTICS INC ARTV 04317A107 $10.4M 0.39% 1,609,569 SH
33 X4 PHARMACEUTICALS INC XFOR 98420X202 $1.4M 0.05% 330,525 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $2.68B 33 0001615982-26-000011
2025-12-31 2026-02-17 $2.02B 27 0001615982-26-000005
2025-09-30 2025-11-14 $1.78B 33 0001615982-25-000006